Causes of Elevated Platelets (Thrombocytosis)
Elevated platelet count (thrombocytosis, defined as platelets ≥450 × 10³/μL) is predominantly secondary (reactive) in approximately 83% of cases, with primary causes accounting for only 12.5% of patients 1.
Primary (Clonal) Causes
Primary thrombocytosis results from myeloproliferative neoplasms (MPNs), most commonly:
- Essential thrombocythemia (ET) - the most frequent primary cause
- Polycythemia vera (PV)
- Primary myelofibrosis (PMF), particularly prefibrotic PMF
- Chronic myeloid leukemia
- Myelodysplastic syndromes with ring sideroblasts and thrombocytosis
Approximately 80% of ET patients harbor driver mutations (JAK2, CALR, or MPL in mutually exclusive fashion), with an additional 50% carrying other mutations including TET2, ASXL1, DNMT3A, and SF3B1 2. Among patients with primary thrombocytosis, 86% have at least one molecular marker indicative of MPNs 1.
Secondary (Reactive) Causes
The major causes of secondary thrombocytosis, in order of frequency, are 1:
- Tissue injury/surgical complications (32.2%) - particularly postoperative states, trauma, burns
- Infection (17.1%) - acute or chronic infectious processes
- Chronic inflammatory disorders (11.7%) - including inflammatory bowel disease, rheumatologic conditions
- Iron deficiency anemia (11.1%) - a frequently overlooked cause
- Malignancy - solid tumors (non-hematologic)
- Splenectomy/asplenia - functional or anatomic
- Medications - including all-trans retinoic acid, epinephrine
- Hemorrhage
- Hemolysis
- Rebound thrombocytosis - following recovery from bone marrow suppression
Critical Distinguishing Features
Platelet count magnitude and thrombosis risk differ significantly between primary and secondary causes 1:
- Primary thrombocytosis: Higher median platelet counts and significantly increased thrombosis incidence
- Secondary thrombocytosis: Lower platelet counts, rarely causes vascular complications beyond treatment of underlying condition 3
Extreme thrombocytosis (platelets >1000 × 10³/μL) occurs in only 0.7% of all thrombocytosis cases and is multifactorial in 79.3% of patients 4. In these extreme cases, surgical complications (54.1%) and hematologic malignancies (27.9%) are the dominant causes, with important differences by setting:
- Inpatients: Surgical complications (71.9%), splenectomy (50.5%), infections (44.9%)
- Outpatients: Hematologic malignancies (56.9%), iron deficiency (36.7%), previous splenectomy (28.4%)
Clinical Pitfalls
Extreme thrombocytosis (≥1500 × 10³/μL) paradoxically increases bleeding risk through acquired von Willebrand disease, not thrombosis risk 5. In fact, some studies show platelet counts >1000 × 10³/μL are associated with lower rates of thrombosis in ET patients 6.
Occult hematologic malignancies are uncommon (12.5% of cases) when other major secondary causes are present 4, but new diagnoses of hematologic malignancy are 1.9 times more likely in outpatients than inpatients (15.6% vs 8.2%).
Leukocytosis at diagnosis has inconsistent prognostic significance - some studies associate it with higher thrombosis risk in PV and ET, while others show this may only be significant in patients <60 years or may not be associated with subsequent thrombosis at all 6.
Diagnostic Approach Priority
When evaluating thrombocytosis 7:
- Repeat CBC with differential and peripheral smear to confirm persistence and exclude spurious causes
- Assess for secondary causes based on clinical context (infection, inflammation, iron deficiency, malignancy, recent surgery/trauma)
- If persistent without identified cause: Test for JAK2 mutation, then CALR and MPL if JAK2-negative
- Bone marrow biopsy when essential thrombocythemia suspected to exclude prefibrotic myelofibrosis
The revised International Prognostic Score of Thrombosis for ET (IPSET-Thrombosis) should be calculated to stratify risk and guide management decisions regarding aspirin and cytoreductive therapy 7.